Tigecycline targets nonsmall cell lung cancer through inhibition of mitochondrial function

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Nonsmall cell lung cancer (NSCLC) presents a significant therapeutic challenge due to its high mortality rate.
• Developing targeted agents that are effective against NSCLC cells while sparing normal cells is a critical research area.

Purpose of the Study:

• To investigate the efficacy of tigecycline, an FDA-approved antibiotic, as a potential therapeutic agent against NSCLC.
• To explore the mechanisms underlying tigecycline's action on NSCLC cells, including its effects on proliferation, apoptosis, and mitochondrial function.

Main Methods:

• Assessed tigecycline's effects on proliferation, apoptosis, and colony formation in various NSCLC cell lines (adenocarcinoma and squamous cell carcinoma).
• Compared the impact of tigecycline on NSCLC cells versus normal fibroblast cells.
• Evaluated tigecycline's in vivo efficacy in inhibiting NSCLC tumor growth.
• Investigated tigecycline's effects on mitochondrial respiration, membrane potential, ATP levels, and reactive oxygen species (ROS) production.

Main Results:

• Tigecycline demonstrated preferential targeting of NSCLC cells, inhibiting proliferation and inducing apoptosis across different subtypes.
• The drug significantly inhibited NSCLC cell colony formation and tumor growth in vivo.
• Tigecycline exhibited a lesser impact on the proliferation and survival of normal fibroblast cells compared to NSCLC cells.
• Tigecycline was found to impair mitochondrial functions by inhibiting respiration, reducing membrane potential and ATP levels, and increasing ROS.

Conclusions:

• Tigecycline shows significant therapeutic potential for nonsmall cell lung cancer.
• Targeting mitochondrial function represents a promising new therapeutic strategy for NSCLC.